PMID- 15364304
OWN - NLM
STAT- MEDLINE
DCOM- 20050201
LR  - 20071115
IS  - 0924-8579 (Print)
IS  - 0924-8579 (Linking)
VI  - 24 Suppl 1
DP  - 2004 Sep
TI  - Newer carbapenems for urinary tract infections.
PG  - S35-8
AB  - Four carbapenems have been available clinically in Japan. These are 
      imipenem/cilastatin (IMIP/CS) and panipenem/ betamipron (PANI/BP) of the older 
      compounds and newer carbapenems such as biapem (BIAP) and meropenem (MERO). The 
      latter compounds are relatively stable to dehydropeptidase-1 (DHP-1) and have 
      been reported to have higher antimicrobial activities compared to the earlier 
      carbapenems. The antimicrobial activity of these four carbapenems against fresh 
      urinary isolates showed high activities against Enterobacteriacae such as 
      Serratia marcescens, Enterobacter cloacae, Citrobacter freundii and Escherichia 
      coli containing the class C-beta-lactamase- and extended spectrum beta-lactamase 
      (ESBL)-producing strains compared to piperacillin (PIPC) and ceftazidime (CTAZ). 
      Against Pseudomonas aeruginosa, the carbapenems, with the exception of panipenem 
      showed strong antimicrobial activities compared to PIPC and CTAZ. High activities 
      were also seen against Enterococcus faecalis, Staphylococcus aureus and 
      Staphylococcus epidermidis, but methicillin-resistant strains were not affected. 
      The first generation carbapenems showed better activity against E. faecalis than 
      newer carbapenems. All four carbapenems were similar in clinical effectiveness in 
      double blind trials for complicated urinary tract infections (UTIs). However, 
      PANI/BP is less effective in UTIs caused by P. aeruginosa than IMIP/CS. MERO 
      showed better eradication rate of P. aeruginosa than IMIP/CS. Retrospective 
      analysis of treated cases using carbapenems showed a rapid defervescence in the 
      treatment of febrile complicated UTIs, which were mainly caused by mixed 
      infection of Gram-negative and Gram-positive bacteria, especially those involving 
      P. aeruginosa and E. faecalis.
FAU - Matsumoto, Tetsuro
AU  - Matsumoto T
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, 1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. 
      t-matus@med.uoeh-u.ac.jp
FAU - Muratani, Tetsuro
AU  - Muratani T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Int J Antimicrob Agents
JT  - International journal of antimicrobial agents
JID - 9111860
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Carbapenems)
SB  - IM
MH  - Anti-Bacterial Agents/chemistry/*pharmacology
MH  - Bacteria/*drug effects
MH  - Bacterial Infections/*drug therapy/microbiology
MH  - Carbapenems/chemistry/*pharmacology
MH  - Double-Blind Method
MH  - Enterobacteriaceae/drug effects
MH  - Gram-Positive Cocci/drug effects
MH  - Microbial Sensitivity Tests
MH  - Pseudomonas aeruginosa/drug effects
MH  - Randomized Controlled Trials as Topic
MH  - Urinary Tract Infections/*drug therapy/microbiology
MH  - Urine/microbiology
RF  - 14
EDAT- 2004/09/15 05:00
MHDA- 2005/02/03 09:00
CRDT- 2004/09/15 05:00
PHST- 2004/09/15 05:00 [pubmed]
PHST- 2005/02/03 09:00 [medline]
PHST- 2004/09/15 05:00 [entrez]
AID - S0924857904000925 [pii]
AID - 10.1016/j.ijantimicag.2004.03.001 [doi]
PST - ppublish
SO  - Int J Antimicrob Agents. 2004 Sep;24 Suppl 1:S35-8. doi: 
      10.1016/j.ijantimicag.2004.03.001.